First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial ; volume:30 ; number:1 ; day:4 ; month:12 ; year:2023 ; pages:257-264 ; date:1.2024
Nature medicine ; 30, Heft 1 (4.12.2023), 257-264, 1.2024
- Creator
-
Fizazi, Karim
Azad, Arun A.
Matsubara, Nobuaki
Carles, Joan
Fay, Andre P.
Giorgi, Ugo de
Joung, Jae Young
Fong, Peter C. C.
Voog, Eric
Jones, Robert J.
Shore, Neal D.
Dunshee, Curtis
Zschäbitz, Stefanie
Oldenburg, Jan
Ye, Dingwei
Lin, Xun
Healy, Cynthia G.
Santo, Nicola Di
Laird, A. Douglas
Zohren, Fabian
Agarwal, Neeraj
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41591-023-02704-x
- URN
-
urn:nbn:de:101:1-2024041215365045065216
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:54 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Fizazi, Karim
- Azad, Arun A.
- Matsubara, Nobuaki
- Carles, Joan
- Fay, Andre P.
- Giorgi, Ugo de
- Joung, Jae Young
- Fong, Peter C. C.
- Voog, Eric
- Jones, Robert J.
- Shore, Neal D.
- Dunshee, Curtis
- Zschäbitz, Stefanie
- Oldenburg, Jan
- Ye, Dingwei
- Lin, Xun
- Healy, Cynthia G.
- Santo, Nicola Di
- Laird, A. Douglas
- Zohren, Fabian
- Agarwal, Neeraj
- SpringerLink (Online service)
Other Objects (12)
Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial
Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death
Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer
Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer
Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study
Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
Correlation of [68Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patients
A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer
Comment on: “Enzalutamide: A Step Towards Pharmacokinetic-Based Dosing in Men with Metastatic Castration-Resistant Prostate Cancer”
Identification of key enzalutamide-resistance-related genes in castration-resistant prostate cancer and verification of RAD51 functions
Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer
CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer
Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial
Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death
Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer
Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer
Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study
Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
Correlation of [68Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patients
A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer
Comment on: “Enzalutamide: A Step Towards Pharmacokinetic-Based Dosing in Men with Metastatic Castration-Resistant Prostate Cancer”
Identification of key enzalutamide-resistance-related genes in castration-resistant prostate cancer and verification of RAD51 functions
Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer
CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer
Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial
Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death
Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer
Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer
Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study
Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
Correlation of [68Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patients
A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer
Comment on: “Enzalutamide: A Step Towards Pharmacokinetic-Based Dosing in Men with Metastatic Castration-Resistant Prostate Cancer”
Identification of key enzalutamide-resistance-related genes in castration-resistant prostate cancer and verification of RAD51 functions
Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer